|
Foreward
In the last years, the problem of "rare diseases", i.e. diseases with a very low prevalence
and few or no treatment options has increasingly grown in the scientific
world and in the public opinion. In consideration of the small number of
patients who could benefit from a new therapy, there is a lack of research investments
made by the pharmaceutical industries in this field.
Thus, the current
interest in these diseases is not the result of a choice made by "pharmaceutical
companies", but is due to the initiatives of patients' families, who set up associations
that have managed to draw the attention of the scientific community,
health institutions and the public opinion to the disease and to the needs of
patients and their families.
The history of A.I.S.EA is an emblematic example for every association that
would like to reach the same goals.
Alternating Hemiplegia is a "very rare" disease, with a prevalence of
1/1.000.000, which is well below the minimum prevalence (5/10.000) required
for the disease to be recognized as a "rare disease" by WHO.
The rarity of this disease was a real obstacle to its understanding and diagnosis
by expert physicians, such as neurologists, child neurologists and pediatricians.
Moreover, in Alternating Hemiplegia there are no diagnostic, instrumental,
biochemical and genetic investigations that can provide a pathognomonic and
exclusive picture. This makes it easier to understand the real difficulties related
to a correct diagnosis.
Therefore, the first goal was to drive experts to understand and recognize the
disease.
Thanks to A.I.S.EA which organized meetings and promoted informational
activities, this topic was then included in scientific programs.
This resulted in revealing a number of misdiagnosed cases and so favouring the
growth of the Association.
The Association has always been sensitive to both social matters and the aggregation
and support role towards parents.
But in these last few years its most distinguishing feature was the boost towards scientific research, as its members were aware that no one else would play this
role and that this was the only way available to find a treatment or prevent the
disease.
For this purpose, a Scientific Committee was set up right from the first year.
This Committee consists of experts and specialist physicians in Alternating
Hemiplegia and in those medical fields where research is supposed to develop:
genetics, movement disorders, etc.
The association of patients and the creation of a Clinical Database, linked to a
Bank of biological samples, made it possible to gather extraordinary caserecords.
From the very beginning, the Association was open to international relationships
with similar associations in foreign countries by offering both "hospitality"
to patients’ families and by including international experts in scientific
meetings.
Moreover, with great effort, the Association managed to fund research
projects, which are now giving their first results.
This activity was also recognized and supported by the National Centre for Rare
Diseases of the Italian National Health Ministry.
The White Book describes the different activities of the Association, and provides
an updating on all aspects of the disease.
It is the final product of a close collaboration
between experts and patients’ families and is addressed to both families
and health-care workers involved in the management of the disease.
Knowledge and information are the basis for any social and scientific progress.
This book will certainly give a further contribution to the fight against
Alternating Hemiplegia.
Professor Federico Vigevano
|